Pinto C, et al. - Panitumumab, a monoclonal antibody anti-epidermal growth factor receptor, was tested for activity and safety as a single agent in combination with radiotherapy in low-risk locally advanced rectal cancer (LARC) preoperative treatment. The pathologic complete response rate (the primary endpoint), at only 10.9%, did not reach the specified level considered suitable for further testing. However, a good toxicity profile was shown, with compliance to concomitant administration of panitumumab and external radiotherapy in preoperative treatment of LARC.